(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Nikki Glaser returns as host of the 2026 Golden Globes: Everything the comedian has said about the upcoming awards show - 2Tens of thousands protest as far-right AfD forms new youth group
- 3Farmers call for French blockades over cow disease cull
- 4Instructions to Floss Appropriately and Forestall Gum Sickness
- 5The Benefits of Effective money management for Your Youngsters' Future Monetary Prosperity
- Pick Your #1 Japanese Food
- Consumers advised to dispose of 19 cooking pans due to lead leaching risk, FDA reports
- One perk to marrying Richard Marx later in life? 'We don't have time' for stupid arguments, says Daisy Fuentes.
- Israeli military says it hit dozens of military facilities in Tehran
- 6 US States for Fly Fishing
- A hunger for new experiences Narratives: Motivating Travel and Experience
- US FDA panel to weigh bid to market nicotine pouches as lower-risk than cigarettes
- A NASA spacecraft orbiting Mars may be dead
- Attorney-General to High Court: Gov’t violating draft ruling, risking rule of law
